This year, more than 158,000 Americans are expected to die from lung cancer. That’s a staggering number: it’s more than all the deaths expected from breast, prostate, colon, rectum, bladder and skin cancers combined. But this grim statistic only spurs one lung cancer doctor and scientist to work harder toward a cure.

Related Links:

AW, Horenblas S, Gietema JA, van Leeuwen FE, Schaapveld M
Abstract
Purpose Testicular cancer (TC) treatment increases risk of subsequent malignant neoplasms (SMNs). It is unknown whether changes in TC treatment over time have affected SMN risk. Methods Solid SMN risk was evaluated in a multicenter cohort comprising 5,848 1-year survivors treated for TC before age 50 years between 1976 and 2007. SMN incidence was compared with cancer incidence in the general population. Treatment-specific risks were assessed using multivariable regression in a case-cohort design. Results After a median follow-up of 14.1 years, 350…

Source: Clinical Lung CancerCategory: Cancer & Oncology Authors: Tags: J Clin Oncol Source Type: research

Abstract
Patients with psoriasis have an increased risk of cancer, which may be due to impaired immune surveillance, immune modulatory treatments, chronic inflammation and/or co-risk factors such as obesity. The increase in treatment-independent solid cancers, including urinary/bladder cancers, oropharynx/larynx, liver/gallbladder and colon/rectal cancers, seem to be linked to alcohol and smoking. Lung cancer and nonmelanoma skin cancer are also increased in patients with psoriasis. The risk of nonmelanoma skin cancer increases with age and severity of psoriasis. It is also higher in men, particularly for squamous…

Source: The Australasian Journal of DermatologyCategory: Dermatology Authors: Tags: Australas J Dermatol Source Type: research

CONCLUSION: First Nations people in Canada have disproportionately high rates of certain cancers, providing evidence to support public health policy and programming. More research is needed to identify factors contributing to the significantly lower incidence observed for various cancer types. Novel methods for studying disparities in cancer incidence among First Nations people are required to support ongoing cancer control planning and advocacy.
PMID: 29981110 [PubMed – as supplied by publisher]

Source: Canadian Journal of Public HealthCategory: International Medicine & Public Health Authors: Tags: Can J Public Health Source Type: research

Authors: Wang Y, Lan GB, Peng FH, Xie XB
Abstract
Renal transplantation is associated with an increased risk of cancers at multiple sites; however, the relationships between increased cancer risk and participant characteristics remain unclear. We searched PubMed, Embase, and the Cochrane Library to identify prospective observational studies performed up to July 2017. Totally 11 prospective studies reported data on 79,988 renal transplant recipients were included. Renal transplant recipients were found to display a higher risk of all cancers (standard incidence ratio [SIR]: 2.89; 95% CI: 2.13-3.91; P

Source: OncotargetCategory: Cancer & Oncology Tags: Oncotarget Source Type: research

Conclusions -Lower limb arterial thrombosis was a marker of occult cancer, especially lung cancer, and was an adverse prognostic factor for mortality in common cancers.
PMID: 29540440 [PubMed – as supplied by publisher]

Source: Clinical Breast CancerCategory: Cancer & Oncology Authors: Tags: Circulation Source Type: research

ConclusionsBecause second primary malignancy developed often after achieving CR by dCRT for ESCC, it should be followed carefully.

CONCLUSIONS: Because second primary malignancy developed often after achieving CR by dCRT for ESCC, it should be followed carefully.
PMID: 29520523 [PubMed – as supplied by publisher]

Source: Clinical Breast CancerCategory: Cancer & Oncology Authors: Tags: Int J Clin Oncol Source Type: research

In conclusion, the tumor reactivity of JAA-F11 supports the continued development of JAA-F11 as a targeted cancer therapeutic for multiple cancers, including those with unmet need.
PMID: 29477636 [PubMed – as supplied by publisher]

Source: Translational OncologyCategory: Cancer & Oncology Authors: Tags: Transl Oncol Source Type: research

Date: January 1, 2018
Issue #: 
1537Summary: 
The immune checkpoint inhibitor pembrolizumab (Keytruda– Merck), a programmed death receptor-1 (PD-1) inhibitor, has been granted accelerated approval by the FDA for use in adults and children who have unresectable or metastatic microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) solid tumors that have progressed following trea tment, and do not have any satisfactory alternative treatment options. For metastatic colorectal cancer, the indication is limited to tumors that have progressed following combination treatment w…

Source: The Medical LetterCategory: Drugs & Pharmacology Authors: Source Type: research

Early warning system for cancer return is possible Related items fromOnMedica Searching for a blood test to monitor ovarian cancer Lung cancer blood test Cheap blood test could boost prostate cancer treatment Underused cancer test could improve treatment of colon cancer Blood test may pick up bladder cancer ’s return before symptoms appear





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here